register free | resend password

Pressemitteilungen zu dem Thema biotechnology


Unterkategorien

PresseMitteilungen zu dem Schlagwort biotechnology


Pharmaceutical Companies Poised to Build Infrastructure to Accommodate Real World Evidence, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 11/08/17 -- Real world evidence is poised to play a growing role in drug development during the next three years, but the availability and cost of acquiring data remain key challenges, according to a recently completed study conducted by the .Large pharmaceutical, biotechnology, and contract research organizations plan to increase internal staff dedicated to collection and analysis of real world data by 25% between now and 2020, according to a survey conducted by ...


08.11.2017

Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 09/12/17 -- Although the rate at which investigational drugs received marketing approval in the United States has declined in recent years, the cardiovascular approval rate trailed other drug approvals as a whole, while the time needed to develop cardiovascular drugs rose, according to a recently completed study conducted by the .Approval success rates for cardiovascular compounds fell from about 5.2% for compounds that began clinical testing during 1995-00, to ab ...


12.09.2017

Global Nanobiotechnology Market: An Straight Overview of Growth Factors and Future Prospects 2017 – 2025

According to a recently published report by Brisk Insights, the Global Nanobiotechnology Market is expected to grow at the CAGR of 8.2 % during 2017-2025. The global nanobiotechnology market is segmented on the basis of application, technology and geography. The report on global nanobiotechnology market (by application, technology and geography) provides a detailed overview and predictive analysis of the market. Full report available on Nanobiotechnology Market: Global Industry Size, Growth, Sha ...


07.08.2017

Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 07/13/17 -- Although 10 new opioid products with abuse-deterrent formulations (ADF) have received regulatory approval in the United States, lack of willingness by insurers to reimburse patients for their use is seen as a primary challenge limiting ADF uptake, according to the .According to Tufts CSDD, 96% of all opioid products prescribed in the U.S. in 2015 lacked abuse-deterrent properties, and only four of the 10 opioid products with abuse-deterrent properties ...


13.07.2017

Nerium Biotechnology Shareholders Overwhelmingly Elect All Six Management Nominees to Nerium''s Board

SAN ANTONIO, TEXAS -- (Marketwired) -- 06/30/17 -- Nerium Biotechnology, Inc. ("Nerium" or the "Company") is pleased to announce the voting results of its annual meeting of shareholders (the "Meeting") held on June 29, 2017 in Toronto, Ontario, Canada. This year''s Meeting had extraordinary participation from Nerium''s shareholders, with a total of 31,272,131 common shares, or approximately 85.75% of the outstanding common shares of Nerium, hav ...


30.06.2017

Plandai Biotechnology Ships 1.2 Million Origine 8 Capsules to Coyne Healthcare

LONDON, UNITED KINGDOM -- (Marketwired) -- 05/22/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that it has successfully shipped an order for 1.2 million Origine 8™ capsules to Coyne Healthcare, a nutraceutical and food supplement company based in South Africa. Origine 8™ is comprised of all eight Phytofare® catechins, which are then entrapped in nutrient-protec ...


22.05.2017

Accelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 05/09/17 -- Biopharmaceuticals accounted for 35% of all new drug approvals in the United States from 2006 through 2016, and a robust development pipeline suggests that the recent increased pace of biotech approvals will continue for the next decade, according to a newly completed assessment from the .The annual pace of 13 new biotech products approvals by the U.S. Food and Drug Administration during the study period accelerated to more than 20 per year during 2014 ...


09.05.2017

iBio, Inc. Provides Corporate Update at Annual Shareholders Meeting

NEW YORK, NY -- (Marketwired) -- 05/04/17 -- (NYSE MKT: IBIO), a leader in developing plant-based biopharmaceuticals, announced today that it provided a corporate update at its Annual Shareholders Meeting held in Bryan, TX.Robert B. Kay, iBio''s Chairman and CEO, stated, "Our achievements over the past year have transformed iBio''s business. In this period, we completed the acquisition, recommissioning and expansion of our Texas plant and equipment for development and c ...


04.05.2017

Global Electronic Health Records (EHR) Software Market to Gain Impetus until 2022, Driven by its Wider Acceptance in Hospitals

Albany, New York, May 04, 2017: The healthcare industry is an entity which constantly changes and improves with the advent of new technology. Currently, the rising demand for streamlining electronic healthcare systems is boosting, which is favorably impacting the market of electronic health records software. The use of EHR software has revolutionized the health industry and has offered a whole new world of operational accuracy to the health concerns. A new study, focusing on this growing market ...


04.05.2017

Plandai Biotechnology Receives 1.2 Million Origine 8 Capsule Order From Coyne Healthcare

LONDON, UNITED KINGDOM -- (Marketwired) -- 05/02/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that it has received an order for 1.2 million Origine 8™ capsules from Coyne Healthcare, a nutraceutical and food supplement company based in South Africa, which we expect to ship this week. Origine 8™ is comprised of all 8 Phytofare® catechins, which are entrapped in ...


02.05.2017

Plandai Biotechnology Names Ezra Jones as Vice President of Sales and Marketing

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/28/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that Ezra Jones has been appointed Vice President of Sales and Marketing, a role he assumes from Callum Cottrell-Duffield, who was recently named Chief Operating Officer of Plandaí.Mr. Jones has been involved in sales of nutraceutical branded ingredients for the past ...


28.04.2017

Cocrystal Pharma Receives Investment Through Private Placement

BOTHELL, WA and ATLANTA, GA -- (Marketwired) -- 04/24/17 -- On April 20, 2017, Cocrystal Pharma, Inc. (OTCQB: COCP) (the "Company") closed on proceeds of $3,000,000 in a private placement offering (the "Offering") of 12,500,000 shares of the Company''s common stock at a purchase price of $0.24 per share. The purchasers included one of the members of the Company''s board of directors, Chairman Dr. Raymond F. Schinazi. In addition, OPKO Health, Inc. investe ...


24.04.2017

NutriBullets SuperFood Boost Featuring Plandai Biotechnology''s Phytofare Expected to Hit Retailers in May

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/24/17 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that NutriBullet SuperFood Fat Burning Boost® featuring Plandaí''s Phytofare® Catechin Complex will be available at retail outlets across the United States as early as May 2017. As announced last November, Capital Brands, the makers of NutriBullet SuperFoods, w ...


24.04.2017

Plandai Biotechnology New Chief Operating Officer Provides Outlook and Milestones for 2017

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/17/17 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today released a statement from its new President and Chief Operating Officer, Callum Cottrell-Duffield, providing an overview of the coming twelve months and setting forth the major milestones the Company expects to achieve.Mr. Cottrell-Duffield stated, "Our first agenda item was ...


17.04.2017

SV Life Sciences Changes Name to SV Health Investors to Better Reflect the Firm''s Longstanding Strategy and Focus

BOSTON, MA -- (Marketwired) -- 04/10/17 -- SV Life Sciences has changed its name to , the healthcare and life sciences venture capital and growth equity firm announced today.The new name is geared to better reflect the firm''s longstanding strategy and multi-sector focus. The firm targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital ...


10.04.2017

Apollo Consulting and Trading AG Partner for Biotech JVs and IPO

Zurich (Switzerland), March 29, 2017 – Apollo Consulting & Trading AG advised Swiss-based biotechnology company Biotensidon International AG in all legal matters concerning the build-up of international production capacity for rhamnolipids (natural surfactants). These activities include drafting the company’s IPO strategy and acting as lead consultancy for setting up strategic joint ventures of a German Biotensidon subsidiary with leading key players in their respective industries, among oth ...


29.03.2017

Plandai Biotechnology Names Callum Cottrell-Duffield as New Chief Operating Officer

LONDON, UNITED KINGDOM -- (Marketwired) -- 03/27/17 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that Callum Cottrell-Duffield has been named President and Chief Operating Officer, replacing the Company''s founder, Roger Baylis-Duffield, who will remain Chief Executive Officer. Mr. Cottrell-Duffield has been serving as Vice President of Sales and Marketing ...


27.03.2017

BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory

OAKLAND PARK, FL -- (Marketwired) -- 03/24/17 -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International BioTech company, celebrated the opening of its new laboratory and corporate offices with a ribbon cutting ceremony hosted by the BioStem Technologies executive team. BSEM''s Founder and CEO, Henry Van Vurst, commented, "With the recent regulation changes we amended our original facility design to comply with FDA 503b ...


24.03.2017

Streamlined Development Process for Certain New Drug Applications Is Not Facilitating Shorter Approval Times, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 03/08/17 -- The 505(b)(2) approval pathway for new drug applications in the United States, aimed at avoiding unnecessary duplication of studies performed on a previously approved drug, has not led to shorter approval times, according to a recently completed analysis conducted by the ."While the 505(b)(2) regulatory pathway has been highly successful in bringing new therapies to market from 2009 through 2015, drug products approved under this pathway had a lon ...


08.03.2017

Label-free Array Systems Market to grow substantially with a CAGR of 5.6% during the period 2016- 2024

Albany, New York, February 14, 2017: Market Research Hub (MRH) has recently announced the inclusion of a new study to its market intelligence database, which is entitled as “Label-free Array Systems Market- Global Industry Analysis 2016-2024”. The report analyzes the global market with an in-depth investigation of some of the major regions including North America, Asia-Pacific, Latin America, Europe and Middle East & Africa. Moreover, this report studies the current scenario as well as the ...


14.02.2017

Brown Technical Media Corp. Launches New Microsite Dedicated to Electrical Wholesalers

HOUSTON, TX -- (Marketwired) -- 01/31/17 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTCQB: PBYA) is pleased to announce today that it has launched a new state of the art micro website () targeted towards servicing over 3000 electrical wholesale outfits. Brown''s recent acquisition of National Electric Wholesale Providers (NEWP) has established Brown as one of the largest wholesalers of electrical codes and electrician exam prep materials in the United S ...


31.01.2017

Court Schedules Hearing To Consider Approval Of Settlement Of Derivative Action

NEW YORK, NY -- (Marketwired) -- 01/27/17 -- iBio, Inc. (NYSE MKT: IBIO) On January 20, 2017, the Supreme Court for the State of New York, County of New York, scheduled a hearing to consider approval of a settlement of the derivative action captioned Spencer Savage and Yousef Barakat, Derivatively on Behalf of iBio, Inc., Plaintiffs, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant, ...


27.01.2017

Brown Technical Media Corp. Completes Acquisition of One Exam Prep

HOUSTON, TX -- (Marketwired) -- 01/27/17 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTCQB: PBYA) is pleased to announce today that it has closed the acquisition of One Exam Prep, LLC (OEP), , a Florida limited liability company, pursuant to the executed binding letter of intent announced on December 15, 2016. OEP is in the business of exam preparation with a focus on construction training and certification.OEP is based in Coconut Creek, Florida and offers eLearni ...


27.01.2017

Brown Technical Media Corp. Closes the Acquisition of National Electric Wholesale Providers with $1.2M in Revenue

HOUSTON, TX -- (Marketwired) -- 01/20/17 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTCQB: PBYA) is pleased to announce today that it has closed the acquisition pursuant to the executed binding letter of intent announced on December 2, 2016 to acquire Premier Purchasing and Alliance LLC, a New York limited liability company also known as National Electrical Wholesale Providers (NEWP). NEWP is in the business of servicing electrical wholesalers throughout the Unit ...


20.01.2017

Brown Technical Media Corp. Announces Uplist to the QB Tier of the OTC Markets

HOUSTON, TX -- (Marketwired) -- 01/18/17 -- Brown Technical Media Corp., a division of Panther Biotechnology Inc. (OTCQB: PBYA), an e-commerce company building the first full service training and career advancement brand for the skilled trades, is pleased to announce today that it has been accepted for up listing to the OTCQB effective immediately.To qualify for the listing, Panther has demonstrated that it is current in its reporting requirements to the Securities and Exchange Commission and c ...


18.01.2017

Brown Technical Media Corp. Announces Record Sales for 2016

HOUSTON, TX -- (Marketwired) -- 01/13/17 -- Brown Technical Media Corp., a division of Panther Biotechnology Inc. (OTC PINK: PBYA), is pleased to announce today that it has achieved record sales for the calendar year 2016 for its line of products in e-learning and training, exam preparation, continuing education and compliance materials for career advancement for a wide variety of technical fields. Brown is building the first full service training and career advancement brand for the skilled tr ...


13.01.2017

Poor Physician and Nurse Engagement Contributes to Low Patient Recruitment Rates, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 01/11/17 -- Although physicians and nurses are familiar with, and comfortable discussing, clinical trials, they refer a mere fraction of their patients for these studies, reflecting, in part, a failure by sponsors, contract research organizations, and investigative site personnel to engage health care providers as partners in the clinical research process, according to a recently completed analysis conducted by the .The study, based on a survey of 2,000 physicians ...


11.01.2017

Plandai Biotechnology Announces Share Exchange Between Protext Mobility and Plandai''s South Africa Subsidiary

BOCA RATON, FL -- (Marketwired) -- 01/10/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that it has completed a share exchange between Plandaí Biotechnology South Africa (PTY) LTD "Plandaí SA," and Protext Mobility, Inc. (OTC PINK: TXTM) "Protext", a Delaware company. Under the terms of the Exchange Agreement, Plandaí became the majority owne ...


10.01.2017

Brown Technical Media Corp. Moves into $35 Billion Virtual Reality Market via HVAC Training

HOUSTON, TX -- (Marketwired) -- 01/05/17 -- Brown Technical Media Corp., a division of Panther Biotechnology (OTC PINK: PBYA), is pleased to announce today that it has executed an exclusive distribution and publishing agreement with The Training Center of Air Conditioning and Heating, (). This transaction further expands Brown''s strategy to utilize virtual reality in the eLearning segment of its business.Brown is disrupting the technical vocations training and certification industry ...


05.01.2017

Panther Biotechnology, Inc. Announces Record Date for Biotechnology Milestone Earn-Out Consideration Shares in Response to Recent Positive Feedback from the FDA

HOUSTON, TX -- (Marketwired) -- 12/16/16 -- Panther Biotechnology, Inc. (OTC PINK: PBYA) or Panther, has announced today that it has set a Record Date or Earn-Out Record Date for shareholders of record to participate in the Earn-Out Consideration afforded to the Earn-Out Shareholders pursuant to the Share Exchange Agreement between Panther Biotechnology, Inc. and Brown Technical Media Corp. filed on November 15th, 2016. The record date for Panther shareholders who are eligible to receive the Ea ...


16.12.2016

Brown Technical Media Corp., a Division of Panther Biotechnology Inc., Signs a Binding Letter of Intent to Acquire One Exam Prep

HOUSTON, TX -- (Marketwired) -- 12/15/16 -- Brown Technical Media Corp., () (Brown), a division of Panther Biotechnology, Inc. (OTC PINK: PBYA) (Panther), is pleased to announce today that it has executed a binding letter of intent to acquire One Exam Prep, LLC () (OEP), a Florida limited liability company, which is in the business of exam preparation with a focus on construction training and certification. OEP will be managed as a new division of Panther.Based in Coconut Creek, Florida, OEP of ...


15.12.2016

Plandai Biotechnology, Inc. Announces South African Department of Health Endorses Access to Medicinal Cannabis

LONDON, UNITED KINGDOM -- (Marketwired) -- 12/08/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced the Parliamentary Portfolio Committee on Health in South Africa outlined a clear plan endorsing the need for greater availability of medicinal cannabis to those who suffer from chronic pain. This action may pave the way for parliament to pass the Medical Innovation Bill ...


08.12.2016

Panther Biotechnology Receives Positive Feedback from the FDA

HOUSTON, TX -- (Marketwired) -- 12/07/16 -- (OTC PINK: PBYA) today announced that it has received positive feedback from the submission presented to the U.S. Food and Drug Administration ("FDA") pursuant to a Pre-IND (Investigational New Drug) meeting with the Division of Oncology Products 1 (DOP1) of the Center for Drug Evaluation and Research (CDER) of the FDA. The purpose of the requested meeting was to obtain FDA''s input regarding Panther''s plans for the dev ...


07.12.2016

Brown Publications Inc., a division of Brown Technical Media Corp., Signs an Exclusive Publishing and Distribution Deal with All Purpose Crane Training

HOUSTON, TX -- (Marketwired) -- 12/05/16 -- Brown Publications Inc. (), a division of Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTC PINK: PBYA), is pleased to announce today that it has executed an exclusive publishing and distribution relationship with All Purpose Crane Training of Upland, California. All Purpose Crane Training (AP) (), established in 2008, provides nationwide mobile crane operator and rigging training and assists operators preparing to obtain a n ...


05.12.2016

Brown Technical Media Corp., a division of Panther Biotechnology, Signs a Binding Letter of Intent to Acquire Premier Purchasing and Alliance LLC

HOUSTON, TX -- (Marketwired) -- 12/02/16 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTC PINK: PBYA) is pleased to announce today that it has executed a binding letter of intent to acquire Premier Purchasing and Alliance LLC, a New York limited liability company also known as National Electrical Wholesale Providers (NEWP). NEWP is in the business of servicing electrical wholesalers throughout the United States with electrician related study material including the ...


02.12.2016

Plandai Biotechnology Receives Initial Purchase Order from NutriBullet LLC

LONDON, UNITED KINGDOM -- (Marketwired) -- 11/30/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, is pleased to announce that they have received an initial purchase order from Capital Brands LLC, distributor of the world famous, NutriBullet®, who will feature Phytofare® Catechin Complex as an active ingredient in their nutrient extraction powder mix, "Superfood Fat Burning Boos ...


30.11.2016

Brown Technical Media Corp. Inks Two New Publishing Deals

HOUSTON, TX -- (Marketwired) -- 11/28/16 -- Brown Technical Media Corp., a division of Panther Biotechnology (OTC PINK: PBYA), is pleased to announce today that it has executed two new exclusive publishing relationships. Brown Technical Publications Inc., a subsidiary of Brown Technical Media Corporation (), currently publishes over 100 titles in a wide variety of over 60 technical trades which include electricians, hydraulics, plumbing/pipefitting, HVAC, welding, rigging, petroleum, drilling, ...


28.11.2016

Brown Technical Media Corp., a Division of Panther Biotechnology, Launches a New Web Service Allowing Companies to Book Safety Training Online

HOUSTON, TX and LA JOLLA, CA -- (Marketwired) -- 11/22/16 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTC PINK: PBYA) (Panther), is pleased to announce today that it has completed testing of its new online booking service that allows individuals and companies throughout the United States to choose from over 15 different new courses. Brown utilizes its Houston location for training but is partnered with other facilities throughout the United States to offer rigging ...


22.11.2016

Another iBio Plague Vaccine Patent Issues

NEW YORK, NY -- (Marketwired) -- 11/21/16 -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the issue of a new Canadian patent in the company''s iBioModulator™ thermostable immunomodulator protein portfolio. The new patent, serial number 2692933, is entitled "Yersinia Pestis Antigens, Vaccine Compositions and Related Methods" and issued October 18, 2016. The patent includes claims c ...


21.11.2016

Brown Technical Media Corp., a division of Panther Biotechnology, Announces the Launch of a New Website Targeted for the American Society of Mechanical Engineers

LA JOLLA, CA and HOUSTON, TX -- (Marketwired) -- 11/17/16 -- Brown Technical Media Corp., a division of Panther Biotechnology (OTC PINK: PBYA) (Panther), is pleased to announce today that it has launched its newest and most cutting edge website which will highlight the upcoming 2017 ASME BPVC release.The American Society of Mechanical Engineers (ASME) is a professional association that promotes the art, science, and practice of multidisciplinary engineering and allied sciences around the globe ...


17.11.2016

Outlook for Pediatric Drug Development Looks Promising, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 11/15/16 -- Resources dedicated to creating medicines to meet the unique needs of children have grown steadily since legislation guiding pediatric drug development was enacted in the United States two decades ago, and the outlook for still greater development looks promising, according to a new analysis completed by the .Even though R&D complexity has grown more than 50% since 2008, resources dedicated to pediatric studies have increased across most R&D fu ...


15.11.2016

Panther Biotechnology Announces the Closing of the Merger with Brown Technical Media Corp.

LA JOLLA, CA and HOUSTON, TX -- (Marketwired) -- 11/15/16 -- Panther Biotechnology, Inc. (OTC PINK: PBYA), or Panther, is pleased to announce today that it has executed a share exchange agreement to merge with Brown Technical Media Corp., or Brown, a privately held corporation in Houston, Texas. Brown and Panther have executed a share exchange agreement whereby all of the outstanding capital stock of Brown will be exchanged for 32,000,000 shares of Panther common stock. Brown will be managed as ...


15.11.2016

iBio Expands Product Development Capacity of cGMP Plant

NEW YORK, NY -- (Marketwired) -- 11/10/16 -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced completion of expanded product development capacity of its subsidiary, iBio CMO LLC, for the production of pharmaceutical proteins in hydroponically-grown green plants. This expansion enables iBio CMO''s use of iBio proprietary technologies to conduct concurrent product development work for multiple cl ...


10.11.2016

Plandai Biotechnology Receives Additional R10 Million Funding From the Land and Agriculture Bank of South Africa

LONDON, UNITED KINGDOM -- (Marketwired) -- 11/03/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, is pleased to announce that its South African subsidiary, Green Gold Biotechnologies (Pty) Ltd, received funding commitment in the amount of 10 million rand [approx. $730,000] from the Land and Agriculture Bank of South Africa ("Land Bank"). These monies will be used to suppor ...


03.11.2016

Panther Biotechnology Announces Meeting With U.S. Food and Drug Administration

LA JOLLA, CA -- (Marketwired) -- 10/24/16 -- (OTC PINK: PBYA) today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Divison of Oncology Products 1 (DOP1) of the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) has been granted by FDA. The meeting with the Oncology Division of FDA will take the form of written responses to Panther''s Pre-IND package and questions regarding the development of TRF-DOX, Panther'&# ...


24.10.2016

Nerium Biotechnology Announces the Appointment of Kerry Mitchell to its Board of Directors

SAN ANTONIO, TEXAS -- (Marketwired) -- 10/19/16 -- Nerium Biotechnology, Inc. ("Nerium") announced today the appointment of Kerry Mitchell to its board of directors. Ms. Mitchell has extensive experience as a media executive, with a strong record of building and transforming multi-platform media brands that include some of the most iconic names in Canadian publishing."We are very excited to have Ms. Mitchell join Nerium''s board of directors," said Dennis Knocke, ...


19.10.2016

Panther Biotechnology Requests Pre-IND Meeting With FDA

LA JOLLA, CA -- (Marketwired) -- 10/10/16 -- (OTC PINK: PBYA) today announced that a request for a Pre-IND (Investigational New Drug) meeting with the Division of Oncology Products 1 (DOP1) of the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration ("FDA") has been submitted. The purpose of the requested meeting is to obtain FDA''s input regarding Panther''s plans for the development of TRF-DOX, Panther''s novel transf ...


10.10.2016

Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis

CLEVELAND, OH and COLUMBUS, OH -- (Marketwired) -- 10/04/16 -- Milo Biotechnology today announced its AAV1-FS344 has been granted Orphan Drug designation from the FDA''s Office of Orphan Products Development for treatment of inclusion body myositis. AAV1-FS344 is a gene therapy-delivered follistatin protein that increases muscle strength and function.The program is currently in a Phase I/II trial at Nationwide Children''s Hospital in adult patients with sporadic inclusion bo ...


04.10.2016

EAG Laboratories Appoints Duane Huggett, Ph.D., as Senior Scientific Advisor for Its Environmental Testing Group

SAN DIEGO, CA -- (Marketwired) -- 09/29/16 -- EAG Laboratories, a global scientific services company that provides a broad range of testing services to technology-related industries, today announced the appointment of Duane Huggett, Ph.D., as for the company''s environmental testing group.provides scientific consultation and advice related to environmental fate and toxicology, with particular emphasis in the pharmaceutical and personal care product sectors. He has in-depth expertise ...


29.09.2016

iBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies (Pty) Ltd

NEW YORK, NY -- (Marketwired) -- 09/29/16 -- (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products announced the successful application of its proprietary technologies to achieve the first milestone in its commercial development agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) of South Africa for the development and manufacture of an improved surfactant protein for the treatment of neonatal respiratory distress syndrome ...


29.09.2016

Panther Biotechnology Announces Entry Into Letter of Intent to Acquire Brown Technical Media Corp.

LA JOLLA, CA -- (Marketwired) -- 09/22/16 -- Panther Biotechnology, Inc. (OTC PINK: PBYA), or Panther, a company which has historically been specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders and had previously been operating in the EDGAR filings industry, is pleased to announce today that it has signed a letter of intent relating to a proposed share exchange transaction with Brown Technical Media Corp., or Brown, a privately held c ...


22.09.2016

Diabetes Drug Development Is Riskier Compared to All Drug Development, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 09/20/16 -- Whereas scores of new diabetes and non-diabetes endocrine drugs have been launched since the mid-1990s, and the demand for new therapies continues to grow, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development, according to results of a new study conducted by the .Only one in 13 investigational diabetes drugs that entered clinical testing from 1995 to 2007 ultimately received U.S. marketin ...


20.09.2016

Daxor Corporation Announces Filing of Form N-CSR for June 30, 2016

NEW YORK, NY -- (Marketwired) -- 09/15/16 -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, filed its Form N-CSR on Tuesday, August 30, 2016 disclosing its schedule of portfolio holdings as of June 30, 2016. Copies of the form will be mailed to the Company''s shareholders and will be available on the Company''s website at .Daxor has been reporting as an investment company under the Investment Company Act of ...


15.09.2016

Plandai Biotechnology Announces Agreement in Principal for New Clinical Trials to Evaluate Effectiveness of Phytofare in Treating Type II Diabetes

LONDON, UNITED KINGDOM -- (Marketwired) -- 08/25/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that it has reached an agreement in principal with North West University in South Africa, to begin human clinical trials on the island of Mauritius, a member of the SADC group of African countries, to determine the effectiveness of using Phytofare® catechin complex in re ...


25.08.2016

Implications of Court Decision in Favor of iBio Against Fraunhofer

NEW YORK, NY -- (Marketwired) -- 08/15/16 -- (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, commented further today on the impact of the recent Court decision in favor of iBio in its action against Fraunhofer and particularly to prevent Fraunhofer''s August 8th press release from misleading the public about the implications of the decision.In 2003, iBio engaged a newly-formed part of the German, Fraunhofer GmbH o ...


15.08.2016

iBio, Inc.''s Claims Against Fraunhofer Affirmed by Delaware Chancery Court

NEW YORK, NY -- (Marketwired) -- 08/04/16 -- (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced today that the Delaware Court of Chancery, where litigation brought by iBio against Fraunhofer USA Inc. has been pending, issued a decisive determination on July 29, 2016, in favor of iBio and against Fraunhofer. The Court affirmed iBio''s exclusive ownership of all proprietary rights of any kind to technology in ...


04.08.2016

Global Regenerative Medicine Market Is Poised for Strong Growth, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 07/14/16 -- A strong development pipeline for regenerative medicine (RM) therapies aimed at treating a broad range of unmet medical needs signals rapid growth in global RM product sales that could have significant and positive impacts on public health, according to a newly completed analysis by the .Today, there are 640 privately held and publicly traded companies in Europe, Japan, and the U.S. that are actively engaged in developing RM therapies, said Christopher ...


14.07.2016

Panther Biotechnology Announces the Initiation of Formal Development of Transferrin Doxorubicin Conjugate

LA JOLLA, CA -- (Marketwired) -- 07/14/16 -- Panther Biotechnology, Inc. (OTC PINK: PBYA) (Panther), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that it has initiated the formal drug development process for its lead compound, Transferrin Doxorubicin (TRF-DOX). In April 2015, Panther entered into a definitive agreement with privately held Faulk Pharmaceuticals, Inc. to acqu ...


14.07.2016

Questex Acquires ExL Events

NEWTON, MA -- (Marketwired) -- 07/11/16 -- , a leading global business information and events company, today announced it has acquired Inc., expanding its presence in the global pharmaceutical, life-science and health-care markets.ExL Events, founded in 2004 as ExL Pharma, is the industry leader in developing innovative, educational conferences that serve the pharmaceutical, life-science and health-care communities. Kerry Gumas, Questex president and chief executive officer, said ExL will comp ...


11.07.2016

Plandai Biotechnology Files 10-K for 2015, Discusses Future Filings, 2016 Operating Results, and Company Future

LONDON, UNITED KINGDOM -- (Marketwired) -- 07/06/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today discussed the recent filing of the Company''s financial statements for the year ended June 30, 2015, filed last week on Form 10-K, and announced that the quarterly reports for the first, second and third quarters of the current year being prepared for review. The Company ...


06.07.2016

iBio, Inc. Receives FDA Orphan Drug Designation for Fibrosis Product Candidate

NEW YORK, NY -- (Marketwired) -- 07/05/16 -- (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to iBio''s investigational biotherapeutic product, iBio-CFB03, for the treatment of systemic sclerosis.Systemic sclerosis is a fibrotic disorder that affects connective tissue of skin and internal organs as well as the w ...


05.07.2016

Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome

LOS ANGELES, CA -- (Marketwired) -- 06/29/16 -- (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic devices and medicines, announced today that it has filed a continuation patent, titled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Endonovo''s patent filing covers a process for the production of the adult stem cell secretome and its corresponding administration as a next generation fully ...


29.06.2016

iBio, Inc. Receives New Patent for Its Biotherapeutic Products for Treatment of Fibrosis

NEW YORK, NY -- (Marketwired) -- 06/29/16 -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the issue by the U.S. Patent and Trademark Office on June 14, 201 of a new patent covering the company''s fibrosis therapeutics product pipeline.The new patent, US 9,365,616, on an invention by iBio''s collaborators, Dr. Carol Feghali-Bostwick and colleagues, is entitled "USE OF ENDOSTAT ...


29.06.2016

Plandai Biotechnology Announces Listing on Branded Ingredients Marketplace Website

LONDON, UNITED KINGDOM -- (Marketwired) -- 06/23/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced it has registered the Company and its products on the Branded Ingredients website () as a further step towards increasing product visibility with product developers. Branded Ingredients is a show case for branded ingredients manufacturers, helping them get in direct cont ...


23.06.2016

Texas A&M University System and iBio Execute Joint Development Agreement for Plant-Produced Pharmaceuticals

NEW YORK, NY -- (Marketwired) -- 06/07/16 -- (NYSE MKT: IBIO) - The Texas A & M University System (including Texas A & M University AgriLife Research, and the Texas A & M Institute of Infectious Animal Diseases (IIAD)) ("TAMUS"), has executed a joint development agreement with iBio, Inc., and its subsidiary, iBio CMO LLC in Bryan/College Station, Texas ("iBio") for the establishment of a collaborative program in plant-produced pharmaceuticals.The collaboration w ...


07.06.2016

Plandai Biotechnology to Host Investor Update Conference Call on Friday June 3, 2016 11a.m. ET

LONDON, UNITED KINGDOM -- (Marketwired) -- 06/01/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced it will be hosting an investor update conference call for Friday, June 3, at 11a.m. Eastern Time. The call will feature Board of Directors member and vice president of sales and marketing, Mr. Callum Cottrell-Duffield. The conference call dial-in information is:Date: Jun ...


01.06.2016

Plandai Biotechnology, Inc. Announces New Process That Could Pave the Way to Using Phytofare for Domestic Animals Including Livestock and Pets

LONDON, UNITED KINGDOM -- (Marketwired) -- 05/24/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that it will be expanding the previously announced clinical trial involving poultry to also include a Phytofare® catechin-proPheroid® formulation in grain-based pellets. If successful, this new delivery method could open the door for introducing pH2™ catechins, rich in a ...


24.05.2016

Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 05/10/16 -- Rising drug prices in the United States will lead payers and pharmaceutical benefit managers (PBMs) to increase the number of drugs ineligible for reimbursement, which will challenge drug developers to provide more concrete evidence of clinical superiority and cost-effectiveness of their products, according to a newly completed analysis by the ."Payers are responding to rising drug costs with new, more restrictive formulary management policies,&qu ...


10.05.2016

Plandai Biotechnology, Inc. Announces Vitamin Express to Release New Product Containing Phytofare(R)

LONDON, UNITED KINGDOM -- (Marketwired) -- 05/10/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced VitaminExpress, a highly successful health supplement company based in the European Union, is set to release a new product this month, with Phytofare® Catechin Complex as the main ingredient, which will be incorporated into their current product line. Vitamin Express has ...


10.05.2016

Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients

CLEVELAND, OH and COLUMBUS, OH -- (Marketwired) -- 05/09/16 -- A presentation at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Washington DC described promising safety and initial efficacy data in sporadic inclusion body myositis (sIBM) patients treated with follistatin gene therapy.In total, nine sIBM patients received follistatin gene therapy treatments and have been followed up to four years. No drug related adverse events have been reported in the study, which was ...


09.05.2016

Plandai Biotechnology, Inc. Announces Record Sales Volume for April

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/29/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that April 2016 saw the company sell and ship 425 kilograms of product, representing approximately $60,000 in revenues. In addition, since January, Plandaí announced that customers have released to market a total of ten new branded consumer products that contain Phytofar ...


29.04.2016

Plandai Biotechnology, Inc. Vice President Gives Online Proactive Investors Interview

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/14/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that Callum Cottrell Duffield, Vice President of Sales and Marketing, has recently given a video interview for Proactive Investors. Proactive Investors is a UK-based online investor services company that provides analytics, market reports, and company and industry profil ...


14.04.2016

Plandai Biotechnology, Inc. Announces First Shipment of Product to USA Customers

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/07/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that it has commenced shipping product to customers in the United States, a first for the London-based company that has thus far primarily sold in Africa and Western Europe. The first order, to be delivered by the end of April, will be formulated into nutriceutical produ ...


07.04.2016

Turbopumps and diaphragm pumps utilized

Asslar, Germany, April 4, 2016. Pfeiffer Vacuum, a leading global supplier of vacuum technology, will be introducing new turbopumps and new diaphragm pumps at the analytica show in Munich from May 10 to May 13. “In an increasingly changing competitive environment, Pfeiffer Vacuum is regarded as an ideally placed and very sound company. We are proud that our product developments for use in laboratory technology, analytics and biotechnology have been setting new standards across the entire vacuum ...


06.04.2016

Nerium Biotechnology Seeks Court-Ordered Termination of Business Venture with JO Products

SAN ANTONIO, TEXAS -- (Marketwired) -- 04/05/16 -- Nerium Biotechnology, Inc. ("Nerium" or the "Company") reported today that its subsidiary, Nerium SkinCare, Inc. ("Nerium SkinCare"), has amended its outstanding claim against Nerium International, LLC (the "Distributor"), Jeff Olson and JO Products, L.L.C. to request additional remedies, including a court-ordered winding-up and termination of the Distributor.Nerium SkinCare holds a minority interest in ...


05.04.2016

Plandai Biotechnology, Inc. Announces New Distributor to Boost Worldwide Sales

LONDON, UNITED KINGDOM -- (Marketwired) -- 03/30/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of biopharmaceutical products including the highly bioavailable Phytofare® catechin complex, today announced that it has signed a distribution agreement with California-based AIDP Inc. that will enable them to offer Phytofare® to their established customer base throughout the world. This agreement will create a way for the company to sell to ...


30.03.2016

NRPB & Pharma Innovation Partnerships 2015 -- Highlights

TAIPEI, TAIWAN -- (Marketwired) -- 03/30/16 -- BioBusiness Asia 2015 (BBA) kicked off a series of events and seminars that offered a perspective in Precision Medicine, Bio-ICT, IP strategies and explored global market trends, strategies with big pharma, and open innovation models. Held at CTBC Financial Hall in Nangang, Taipei, BBA provided a networking ground for Taiwan biopharma industry leaders, global researchers and influential pharma speakers. Session III titled , July 23rd, discussed the ...


30.03.2016

Plandai Biotechnology, Inc. Receives Initial Order From Coyne Healthcare

LONDON, UNITED KINGDOM -- (Marketwired) -- 03/15/16 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), biopharmaceutical producer of the highly bioavailable Phytofare® catechin complex, today announced that it has received an initial order for 500,000 capsules of the Company''s Pheroid® entrapped Phytofare® catechin complex -- trade named "ph²™" from Coyne Healthcare, leading developer of high-quality nutraceutical and food supp ...


15.03.2016

Tufts Center for the Study of Drug Development Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published

BOSTON, MA -- (Marketwired) -- 03/10/16 -- The most recent analysis by the Tufts Center for the Study of Drug Development of the average cost to develop and gain marketing approval for a new drug -- pegged at $2.558 billion -- has been published in the Journal of Health Economics, it was announced today.The article, included in the May issue of the Journal of Health Economics, contains more detailed analyses and discussion than were presented in November 2014 when Tufts CSDD first disclosed pri ...


10.03.2016

Promise of Immuno-Oncology Therapies Is Boosting R&D Funding and Alliances, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 03/08/16 -- Investments in research and development for new immuno-oncology (I/O) drugs, along with dramatic improvements in complete response rates in trials for new I/O therapies, are helping to increase the number of alliances between pharmaceutical and biotech companies and university and cancer centers, a new analysis by the shows.Currently, more than 130 biotech and 20 pharma companies are developing I/O therapies, according to Tufts CSDD. That activity, Tu ...


08.03.2016

Plandai Biotechnology, Inc. Announces Relocation of Sales Office to London, England and Other Corporate Changes

LONDON, UNITED KINGDOM -- (Marketwired) -- 03/03/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), a producer of the highly bioavailable Phytofare® catechin complex, today announced that it has relocated its sales offices to London, England, to better accommodate the growing demand for product and maintain a strategic position that accommodates operations in Europe, North America and South Africa. Previously, all sales were handled from the Compan ...


03.03.2016

Plandai Biotechnology, Inc. Announces Release of Grenade Thermo Detonator Using Phytofare

LONDON, UNITED KINGDOM -- (Marketwired) -- 03/02/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that leading nutraceutical brand, Grenade®, is launching a new product, Grenade® Thermo Detonator Stim Free, that incorporates Phytofare® as a key active ingredient. The new cutting edge stimulant-free formula uses a patented dual-release technology to aid those on a die ...


02.03.2016

Nerium Biotechnology Files Claim to Enforce Its Intellectual Property Rights

SAN ANTONIO, TEXAS -- (Marketwired) -- 02/17/16 -- Nerium Biotechnology, Inc. ("Nerium") reported today that it has filed a claim in United States federal court against Nerium International, LLC ("International") and others as a result of the infringement of Nerium''s trademarks and trade dress by products being distributed and sold by International and others, which products are unrelated to Nerium and do not contain Nerium''s proprietary and patented t ...


17.02.2016

Lixte Biotechnology Holdings, Inc.''s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

EAST SETAUKET, NY -- (Marketwired) -- 02/03/16 -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte''s proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published ...


03.02.2016

Plandai Biotechnology, Inc. Announces New Product With Coyne Healthcare

LONDON, UNITED KINGDOM -- (Marketwired) -- 02/02/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced a license agreement with Coyne Healthcare for a new product which will utilize the Company''s Pheroid® entrapped Phytofare® catechin complex -- trade named "ph²™"-- in a high-end consumer product for therapeutic and various other applications. Under t ...


02.02.2016

New Approaches to Patient Recruitment and Retention Anticipate Structural Change in the Clinical Research Enterprise, Tufts Center for the Study of Drug Development Reports

BOSTON, MA -- (Marketwired) -- 01/26/16 -- Responding to strong and growing pressures to accelerate the pace at which new medicines are launched, drug developers are innovating clinical study volunteer recruitment and retention to significantly improve clinical trial performance and efficiency, according to R&D leaders participating in a roundtable recently hosted by the .Some of those new approaches include using Big Data to identify and understand patient populations, engaging the "v ...


26.01.2016

Lixte Completes Private Placement of Convertible Preferred Stock

EAST SETAUKET, NY -- (Marketwired) -- 01/25/16 -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common shares at a per share price of $0.80.Lixte''s CEO, John S. Kovach, M.D., said, "This new investment allows Lixte to pursue opportunities that have emerged regarding our lead anticancer compound, LB-100.First, in the Pha ...


25.01.2016

Plandai Biotechnology, Inc. Announces Phytofare Sales on Three Continents

LONDON, UNITED KINGDOM -- (Marketwired) -- 01/25/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that the Company is actively selling Phytofare® in Africa, Europe and Australia, where various customers use Phytofare® as the active ingredient in their formulated products. Sales of Phytofare® to United States customers are considered imminent, with sales to China anti ...


25.01.2016

iBio Forms Joint Venture CMO for Large-Scale Pharmaceuticals Manufacturing in Green Plants and Accepts Additional Investment

NEW YORK, NY -- (Marketwired) -- 01/14/16 -- iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the formation of a joint venture with affiliates of Eastern Capital Limited (the "Eastern Affiliates") to develop and manufacture plant-made pharmaceuticals.Eastern and iBio have capitalized a newly-formed subsidiary of iBio -- iBio CMO LLC -- to create a contract manufacturing organization for development ...


14.01.2016

Protocol Amendments Improve Elements of Clinical Trial Feasibility, But at High Economic and Cycle Time Cost, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 01/14/16 -- Research sponsors implement at least one substantial global amendment for nearly 60% of all clinical trial protocols, substantially reducing the number of actual patients screened and enrolled, but leading to significantly longer clinical trial durations and higher costs, a newly completed analysis by the concludes.The total median direct cost to implement a substantial amendment for Phase II and Phase III protocols is $141,000 and $535,000, respectiv ...


14.01.2016

Plandai Biotechnology, Inc. Announces Phytofare(R) Used as Key Ingredient in New Fat Burner Product

LONDON, UNITED KINGDOM -- (Marketwired) -- 01/13/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that TNT Supplements recently launched their new product, TNT Fat Burner, in the United Kingdom. TNT contains a unique blend of ingredients that have never before been used in tandem, one of which is Plandaí''s Phytofare® catechin complex. Phytofare® is a highl ...


13.01.2016

CRISPR''s Catch-22: the Promise and Peril of Gene Editing

CAMBRIDGE, MA -- (Marketwired) -- 01/12/16 -- CRISPR is heralded as the biotechnology breakthrough holding the promise of delivering profoundly innovative cures for diseases through gene editing and manipulation.Short for Clustered Regularly-Interspaced Short Palindromic Repeats, CRISPR also raises a host of ethical questions that the industry is grappling with -- even as it explores dozens of potential new approaches for treating illnesses ranging from cancer to muscular dystrophy and other ge ...


12.01.2016

Drug Developers Are Working to Boost R&D Productivity, But Need to do More to Achieve Large-Scale Improvements, According to Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 01/07/16 -- While drug developers during the coming year will continue their efforts to meet the growing demand for innovative new medicines, they must also significantly scale up their level of process improvements if they are to reduce the time and cost required to bring new drugs to market, according to the ."The core challenge is that developing new drugs has become more complex and more expensive than ever," said Tufts CSDD Director Kenneth I Kaitin ...


07.01.2016

Plandai Biotechnology, Inc. Gives Annual Report of Progress and Provides Projections for 2016

LONDON, UNITED KINGDOM -- (Marketwired) -- 12/28/15 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), a producer of highly bioavailable Phytofare® Catechin Complex, today reviewed the results and current standings for 2015 and discussed plans for the future as they look to 2016.Roger Baylis-Duffield, Chief Executive Officer for Plandaí, stated, "Earlier in 2015, the company commenced production and sale of its Phytofare® Catechin Complex, a gree ...


28.12.2015

ContraFect to Present at 27th Annual Piper Jaffray Healthcare Conference

YONKERS, NY -- (Marketwired) -- 11/30/15 -- (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company''s chief executive officer, will participate in an analyst-led fireside chat at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015 at 4:00 PM ET in New York, NY. ...


30.11.2015

iBio Continues Global Expansion of Intellectual Property

NEW YORK, NY -- (Marketwired) -- 11/30/15 -- iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, announced it has received notice from the European Patent Office that the opposition period for a patent granted to iBio has expired and no opposition has been filed."This patent strengthens protection of our innovative plant-made protein production technology," stated Robert Erwin, iBio''s President. "In c ...


30.11.2015

ContraFect Corporation to Announce Third Quarter 2015 Results on November 12, 2015

YONKERS, NY -- (Marketwired) -- 11/05/15 -- (NASDAQ: CFRX) (NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced that it will report financial results for the third quarter ended September 30, 2015 on Thursday November 12, 2015.ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibod ...


05.11.2015

Plandai Biotechnology, Inc. Announces Distribution Agreement With Bal Pharma Ltd Covering India

LONDON, UNITED KINGDOM -- (Marketwired) -- 10/27/15 -- Plandaí Biotechnology, Inc. ("Plandaí" or "the Company") (OTCQB: PLPL), producer of the highly bioavailable Phytofare®, today announced that it has executed an Exclusive Distribution Agreement with Bal Pharma Ltd., an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients (). Under the terms of the agreement, Bal Pharma will use the Company� ...


27.10.2015

Innovation in Drug Development Process Remains a Key Challenge, Tufts Center for the Study of Drug Development Says

BOSTON, MA -- (Marketwired) -- 10/20/15 -- Although pharmaceutical companies have long aspired to improve drug development efficiency, the drug development process remains highly inefficient and fraught with delays and rising costs, according to R&D leaders participating in a roundtable recently hosted by the ."Drug development cycle times have not gotten faster, costs continue to increase, and drug development has become riskier than ever with only 11.8% of products that enter clinica ...


20.10.2015

ContraFect to Present at 14th Annual BIO Investor Forum

YONKERS, NY -- (Marketwired) -- 10/13/15 -- (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company''s chief executive officer, will present a corporate overview at the 14th Annual BIO Investor Forum on Tuesday October 20, 2015 at 10:30 AM PT (1:30 PM ET) in San Francisco, CA ...


13.10.2015



All members: 9 376
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 54


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.